DiaMedica Therapeutics (DMAC) Cash & Equivalents (2017 - 2026)

DiaMedica Therapeutics' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $4.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 88.03% year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $4.9 million, a 88.03% increase from a year earlier, with the FY2025 full-year figure at $15.6 million, up 417.26% from the prior year.
• Cash & Equivalents slipped to $4.9 million in Q1 2026 per DMAC's latest filing, from $15.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $15.6 million in Q4 2025 and bottomed at $2.1 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $3.3 million (2025), against an average of $4.8 million.
• Across the five-year window, Cash & Equivalents sank 82.92% in 2022 and soared 417.26% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $4.7 million in 2022, then retreated by 3.91% to $4.5 million in 2023, then sank by 33.41% to $3.0 million in 2024, then surged by 417.26% to $15.6 million in 2025, then sank by 68.89% to $4.9 million in 2026.
• Per Business Quant, the three latest DMAC Cash & Equivalents figures stand at $4.9 million (Q1 2026), $15.6 million (Q4 2025), and $3.3 million (Q3 2025).